Professor Hirohide Saito and his research team have developed a new microRNA-responsive hybrid mRNA switch, enabling precise, ...

The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Everest Medicines unveils breakthroughs in AI+mRNA platform, reinforces global leadership in next-gen mRNA innovation: Hong Kong Monday, July 7, 2025, 10:00 Hrs [IST] Everest Medi ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.